The human MT 1 and MT 2 melatonin receptors 1,2 are G-proteincoupled receptors (GPCRs) that help to regulate circadian rhythm and sleep patterns 3 . Drug development efforts have targeted both receptors for the treatment of insomnia, circadian rhythm and mood disorders, and cancer 3 , and MT 2 has also been implicated in type 2 diabetes 4,5 . Here we report X-ray free electron laser (XFEL) structures of the human MT 2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon 6 D; these were essential for determination of the high-resolution structure of both MT 2 and MT 1 8 . To promote crystal contacts, we used a double-fusion approach, with rubredoxin 11 in the intracellular loop 3 (ICL3) and thermostabilized apocytochrome b 562 RIL (BRIL) 11 attached to the receptor N terminus. Radioligand binding assays revealed a 120-fold reduction in melatonin binding affinity (approximately 30-fold reduction at physiological concentration of NaCl), probably owing to stabilization of the crystallized construct in an inactive 'low agonist affinity' state that is deficient in G-protein coupling and signalling 9,12 (Extended Data Table 1 ). All four MT 2 structures were obtained using lipidic cubic phase (LCP) 13 crystallization (Extended Data Fig. 1 , Extended Data Table 2 ). The overall receptor conformation was similar in all four structures (Cα root mean squared deviation (r.m.s.d.) < 0.3 Å), so we used the highest resolution MT 2 -2-PMT structure in the analysis below unless otherwise noted.
. Drug development efforts have targeted both receptors for the treatment of insomnia, circadian rhythm and mood disorders, and cancer 3 , and MT 2 has also been implicated in type 2 diabetes 4,5 . Here we report X-ray free electron laser (XFEL) structures of the human MT 2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon 6 2 , but in addition the MT 2 structures reveal a narrow opening towards the solvent in the extracellular part of the receptor. We provide functional and kinetic data that support a prominent role for intramembrane ligand entry in both receptors, and suggest that there might also be an extracellular entry path in MT 2 . Our findings contribute to a molecular understanding of melatonin receptor subtype selectivity and ligand access modes, which are essential for the design of highly selective melatonin tool compounds and therapeutic agents.
To improve the low surface expression and stability of wild-type MT 2 , we introduced eight point mutations on the basis of homology to other class A receptors: D86 2.50 N (ref. 9 ), L108 ECL1 F, F129 3.41 W (ref. 10 ), N137 3.49 D, C140 3.52 L, W264 6.48 F, A305 7.50 P, and N312 8.47 D; these were essential for determination of the high-resolution structure of both MT 2 and MT 1 8 . To promote crystal contacts, we used a double-fusion approach, with rubredoxin 11 in the intracellular loop 3 (ICL3) and thermostabilized apocytochrome b 562 RIL (BRIL) 11 attached to the receptor N terminus. Radioligand binding assays revealed a 120-fold reduction in melatonin binding affinity (approximately 30-fold reduction at physiological concentration of NaCl), probably owing to stabilization of the crystallized construct in an inactive 'low agonist affinity' state that is deficient in G-protein coupling and signalling 9, 12 (Extended Data Table 1 ). All four MT 2 structures were obtained using lipidic cubic phase (LCP) 13 crystallization (Extended Data Fig. 1 , Extended Data Table 2 ). The overall receptor conformation was similar in all four structures (Cα root mean squared deviation (r.m.s.d.) < 0.3 Å), so we used the highest resolution MT 2 -2-PMT structure in the analysis below unless otherwise noted.
MT 2 adopts the canonical seven-transmembrane-domain (7TM) fold of class A receptors, with the short amphipathic helix VIII parallel to the membrane on the intracellular side (Fig. 1a) . As in MT 1 8 , the 7TM bundle of MT 2 is found in an inactive conformation. Restoration of the function-impairing D86 2.50 N mutation (Extended Data Table 3 ) allowed us to solve the MT 2 (N86D)-2-PMT structure at a lower resolution and showed that this mutation had no major effect on the overall These authors contributed equally: Linda C. Johansson, Benjamin Stauch. *e-mail: bryan_roth@med.unc.edu; katritch@usc.edu; cherezov@usc.edu Letter reSeArCH receptor conformation, as also supported by molecular dynamics simulations ( Supplementary Fig. 1 ). Structural comparison of MT 2 and MT 1 -which share 68% sequence identity-revealed notable overall similarity (Cα r.m.s.d. < 0.6 Å), with all ligand-interacting residues conserved 8 ( Fig. 1d, Extended Data Fig. 2c ). There is a common pharmacophore between receptor subtypes that consists of aromatic stacking of the ligand core with F192
ECL2
, as well as hydrogen bonds between the methoxy group of 2-PMT and N175 4.60 and between the alkylamide tail of the ligand and Q194 ECL2 (Fig. 1c, d ). The stability of these ligand-anchoring interactions was confirmed by molecular dynamics simulations (Extended Data Fig. 3 ). Further, mutation of F192 ECL2 to isoleucine or alanine caused loss of ligand binding and signalling (Extended Data Tables 1, 4) , as also observed for MT 1 8 . In contrast to MT 1 , however, mutation of N175 4.60 to alanine in MT 2 did not impair receptor function, which indicates that this residue has different roles in the activation of the two receptor subtypes. Mutation of either Q194 ECL2 or N268 6.52 to alanine had only minor effects on receptor ligand affinity, receptor activation or stability (Extended Data Tables 1, 4 , 5), whereas the double mutation Q194 ECL2 A/N268 6.52 A results in a marked loss of receptor activity (Extended Data Tables 4, 5 ), which suggests that these residues show functional redundancy in MT 2 . Notably, despite the binding site residues being conserved between the two receptors, we observed subtle conformational differences between them, such as in the side chains of Y200
5.38 and Y294 7.39 and in the backbone region surrounding P174 4 .59 (Extended Data Fig. 2d) . Furthermore, the binding pocket of MT 2 is about 50 Å 3 (7%) larger than that of MT 1 , with most of the volume difference attributed to the region around the alkylamide tail and the hydrophobic subpocket that accommodates substituents of melatonin analogues in our structures (Fig. 1d, Extended Data Fig. 2b ). These regions have a key role in MT 2 selectivity, as discussed below.
Structural analysis of MT 2 revealed an opening between helices IV and V from the orthosteric ligand binding site to the membrane (Fig. 2a) . This channel is similar to that seen in MT 1 , but is more constricted (around 2.6 Å in diameter at the narrowest part). Comparison of the structures of MT 2 and MT 1 revealed that Y200 5.38 in MT 2 makes a hydrogen bond to N175 4.60 , constricting the channel, whereas in MT 1 it adopts a different conformation, pointing towards the lipid interface ( Fig. 2a-c, Extended Data Fig. 2c, d ). In our MT 2 (H208A)-2-PMT structure, mutating H208 5.46 near the channel entrance to alanine further closes off the opening by an approximately 0.9 Å inward shift of helix V (Extended Data Fig. 4 ). This finding suggests that H208 5.46 helps to control the channel entrance, albeit only moderately influencing ligand affinity and receptor function in MT 2 (Extended Data Tables 1, 4) . Further analysis of the MT 2 structures revealed a potential secondary access route to the orthosteric binding site from the solvent-exposed extracellular (ECL) region (Fig. 2d) . This second opening has a slightly larger diameter (about 2.5-3 Å) and is lined by aromatic Y294
7.39 and hydrophilic T191 ECL2 and Q194 ECL2 residues (Fig. 2e) . In MT 1 , the corresponding residues Q181 ECL2 and Y281 7.39 adopt different conformations, completely sealing off this entrance (Fig. 2f) . 
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To test the relative importance of these two putative binding site access routes, we performed kinetic ligand dissociation studies on both receptors using [ ) is substantially longer in wild-type MT 2 than in MT 1 , which suggests that the narrower membrane entry channel restricts ligand access (Fig. 2g, h ). Mutation of the membrane channel-lining residue Y 5.38 A, designed to widen the access channel, caused a 30-fold decrease in residence time for MT 2 (with similar ligand affinity), while the corresponding mutation in MT 1 caused a more-modest decrease in residence time, consistent with the wider channel and a different conformation of Y 5.38 in MT 1 . To constrict the channel, we mutated A 4.56 , a key residue at the interface of helices IV and V in both receptors, into a bulkier methionine. This mutation markedly increased residence time for both receptors ( Fig. 2g, h ), reaching up to 20 h in MT 2 , which suggests that this channel is important for ligand access in both receptors.
When we tested mutations designed to widen the ECL opening in both receptors, ligand residence time was reduced more than tenfold in MT 2 mutants T191 ECL2 A and Q194 ECL2 A, and roughly fivefold with the equivalent ECL2 mutations in MT 1 (Fig. 2g, h ). The MT 2 (Y294 7.39 A) mutant showed an even greater decrease in ligand residence time (22-fold) relative to the wild type, whereas the equivalent MT 1 mutant showed a similar residence time to the wild type. These differences can be reconciled if ligand site access through the ECL entrance is more important in MT 2 than in MT 1 , consistent with the crystal structures, in which residue Y294 7.39 adopts a different conformation in MT 2 , allowing easier ligand egress through the ECL opening.
The elucidation of high-resolution structures of both melatonin receptor subtypes and published ligand structure-activity relationship (SAR) data 14, 15 allowed us to establish a model of receptor subtype ligand selectivity. To this end, we used molecular docking of several available selective ligands to both receptors. Docking of the moderately MT 1 -selective compound 5-hydroxyethoxy-N-acetyltryptamine (5-HEAT) 16 and the bitopic ligand CTL 01-05-B-A05 8 suggests thatalthough an extension or substitution of the R 1 position by a linear alkyl chain can be accommodated by the membrane access channel in both MT 1 and MT 2 (Fig. 3a, c) -the narrower MT 2 channel renders binding of the extended portion of the bitopic ligands suboptimal owing to potential steric clashes. Accordingly, the H208 5.46 A mutation in MT 2 abolished the efficacy of CTL 01-05-B-A05 as a G i agonist (Extended Data Fig. 4d ), probably by further restricting the channel and/or eliminating the hydrogen bond between H208 5.46 and CTL 01-05-B-A05 that was observed in docking to MT 1 8 . This mutation had a negligible effect on monotopic ligand binding and function (Extended Data Tables 1,  4 , 5), which suggests that a sufficiently wide membrane channel (as in MT 1 ) is essential for accommodation of bitopic ligands.
The MT 2 -selective ligands IIK7 and DH97 (both of which are about 90-fold selective) 17, 18 adopt 'tail up' binding modes similar to that of 2-PMT, with their alkylamide tails (R 2 position in Fig. 3b , c) interacting with Q194
ECL2
. By contrast, in MT 1 the longer alkylamide tails of these ligands avoid this upward tail position owing to steric clashes, and can adopt only suboptimal 'tail down' conformations. Bulky substituents in the R 3 position confer MT 2 selectivity by using the larger hydrophobic subpocket of the receptor (Fig. 3b, c) . In summary, our analysis suggests that R 1 substituents are important for MT 1 selectivity, while R 2 and R 3 mostly convey selectivity towards MT 2 (Fig. 3c) . The slightly larger binding site in MT 2 also helps to achieve selectivity, as reflected by the larger number of compounds that are moderately selective for MT 2 (Extended Data Fig. 5 ). Subtype-selective compounds are desirable owing to the involvement of MT 2 in type 2 diabetes, for which a number of single nucleotide polymorphisms (SNPs) have been reported 4, 5 . When we mapped these sites onto our MT 2 structure, we observed clustering of residues in the vicinity of the ligand binding pocket and on the receptor surface, along the membrane interface of helices I and II and the intracellular G-protein and β-arrestin binding regions (Fig. 4) Mapping of residues implicated in type 2 diabetes 4,5 onto the MT 2 crystal structure. Gold, residues in which mutations lead to defects in two or more pathways; cyan, G-protein-specific defects; blue, β-arrestin-2-specific defects; magenta, ERK-specific defects; green, mutations that abolish melatonin binding; grey, mutations similar to the wild type. Type-2-diabetes-related mutations in residues not observed in the crystal structure are not shown. I/V and V124 3.36 I variants are located in the hydrophobic subpocket of the receptor, which could influence ligand binding and affect subsequent signalling pathways 4, 5 . The structural basis of melatonin receptor subtype selectivity revealed here has the potential to inspire a new generation of highly selective pharmacological tools that will help to further dissect the melatonin system. We also provide insights into differences in ligand entry between the two receptors by demonstrating the potential of MT 2 to support extracellular ligand access to the binding pocket. This difference in ligand entry can be exploited to facilitate melatonin receptor subtype selectivity, as the ECL route in MT 2 could accommodate more polar compounds compared to the membrane-buried channel. We therefore expect that our results will lead to new therapies involving these pleiotropic receptors, aimed at-but not limited to-the treatment of type 2 diabetes, cancer and sleep disorders.
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of these residues could point to their involvement in interactions with intracellular and
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Design and expression of MT 2 crystallized construct. The DNA sequence of human MT 2 receptor (UniProt 21 identifier P49286) was synthesized by GenScript with optimization for expression in insect cells. The crystallized construct (MT 2 -CC) has truncations of N-terminal residues 1-30 and C-terminal residues 341-362. The thermostabilized apocytochrome BRIL (UniProt P0ABE7) from Escherichia coli with mutations M7W, H102I and R106L was fused to the truncated N terminus of MT 2 with a six-residue linker (GDGARP). Another fusion protein, rubredoxin (Rub, UniProt P00268), was fused in ICL3, replacing receptor residues 232-240. For construct optimization (to increase monodispersity, thermostability and crystallizability), the following point mutations were added: D86 8.47 D (see the accompanying paper 8 for details). The MT 2 -CC coding sequence was subcloned into a modified pFastBac1 (Invitrogen) vector, with a haemagglutinin (HA) signal sequence and a Flag tag on the N terminus and a PreScission protease cleavage site followed by a 10× His tag on the C terminus. The receptor was expressed in Spodoptera frugiperda cells (Sf9, purchased from ATCC, CRL-1711, authenticated by supplier using morphology and growth characteristics, certified mycoplasma-free), which were collected and stored as described in the accompanying paper 8 .
Purification of MT 2 -CC.
Insect cell membranes were prepared by thawing frozen cell pellets in a hypotonic buffer containing 10 mM HEPES (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, and homemade protease inhibitor cocktail. Extensive washing of the raw membranes was performed by repeated Dounce homogenization and centrifugation in hypotonic buffer (once), followed by high osmotic buffer containing 1.0 M NaCl, 10 mM HEPES (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, and homemade protease inhibitor cocktail (two or three times), thereby separating soluble and membrane-associated proteins from integral membrane proteins. Stocks (100 mM) of 2-PMT (Tocris) and ramelteon (Apex Biosciences) were dissolved in DMSO. Washed membranes were resuspended into a buffer containing 50 μM 2-PMT or ramelteon, 2 mg ml -1 iodoacetamide, and homemade protease inhibitor cocktail, and incubated at 4 °C for 30 min before solubilization. The membranes were then solubilized in 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% (wt/vol) n-dodecyl-β-d-maltopyranoside (DDM, Anatrace), 0.2% (wt/vol) cholesteryl hemisuccinate (CHS, Sigma-Aldrich) at 4 °C for 3 h. The supernatant was isolated by centrifugation at 60,000g for 50 min, and incubated in 20 mM HEPES (pH 7.5), 800 mM NaCl with Talon (immobilized metal affinity chromatography IMAC) resin (Clontech) overnight at 4 °C. After binding, the resin was washed with twenty column volumes of wash buffer 1 (50 mM HEPES (pH 7.5), 50 μM 2-PMT or ramelteon, 800 mM NaCl, 10% (vol/vol) glycerol, 0.1% (wt/vol) DDM, 0.02% (wt/vol) CHS, 10 mM imidazole), followed by ten column volumes of wash buffer 2 (50 mM HEPES (pH 7.5), 50 μM 2-PMT or ramelteon, 150 mM NaCl, 10% (vol/vol) glycerol, 0.05% (wt/vol) DDM, 0.01% (wt/vol) CHS, 50 mM imidazole). The protein was then eluted in minimal volumes of elution buffer (50 mM HEPES (pH 7.5), 50 μM 2-PMT or ramelteon, 150 mM NaCl, 10% (vol/vol) glycerol, 0.02% (wt/vol) DDM, 0.01% (wt/vol) CHS, 220 mM imidazole). PD MiniTrap G-25 columns (GE Healthcare) were used to remove imidazole. The protein was then treated overnight with His-tagged PreScission protease (GenScript) to cleave the C-terminal His-tag. PreScission protease and the cleaved C-terminal fragment were removed by binding to Talon IMAC resin for 1.5 h at 4 °C. The protein was collected as the TALON IMAC column flow-through. The ligand concentration was increased to 100 μM, and the protein was concentrated to 30-40 mg ml -1 with a 100-kDa molecular mass cut-off Vivaspin centrifuge concentrator (Sartorius). Protein stability assays. The stability of purified MT 2 -CC was analysed using a microscale thermostability assay 22 using Rotorgene (QIAGEN). In brief, 1-5 μg of protein was mixed with 1.5 μM 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcoumarin (CPM) dye (2.5 mM stock in DMSO) in 25 mM HEPES pH 7.5, 150 mM NaCl, 0.02% DDM (wt/vol), 0.004% CHS (wt/vol), 10% glycerol (vol/vol), and indicated concentrations of compounds to a final volume of 100 μl. Samples were incubated for 15 min at 20 °C and then heated gradually from 25 °C to 95 °C at a rate of 2 °C min -1 , monitoring CPM fluorescence (excitation 365 nm, emission 460 nm). The melting temperature (T m ) was determined using the derivative of the resulting melting temperature curve after background subtraction using Prism 7.0 (GraphPad). Crystallization. Purified MT 2 -CC in complex with 2-PMT or ramelteon was reconstituted into LCP by mixing it with molten lipid using a mechanical syringe mixer 13 . The protein-LCP mixture contained 40% (wt/wt) receptor solution, 54% (wt/wt) monoolein, and 6% (wt/wt) cholesterol. Crystallization trials were performed in 96-well glass sandwich plates (Marienfeld) using an NT8-LCP robot (Formulatrix) by dispensing 40 nl of protein-laden LCP and 800 nl of precipitant solution per well. Plates were incubated and imaged at 20 °C using an automatic incubator/imager (RockImager 1000, Formulatrix). Initial crystal hits were identified in a condition containing 100 mM HEPES, pH 6.8, 30% (vol/vol) PEG 400, 100 mM NH 4 CH 3 CO 2 . These crystals, approximately 30 × 30 × 70 μm 3 , were collected using micromounts (MiTeGen) and flash-frozen in liquid nitrogen for data collection at a microfocus synchrotron source. After extensive optimization, the best crystals diffracted to about 3.0 Å resolution, but suffered from radiation damage, resulting in a 3.5 Å complete dataset. Additives had no effect on diffraction quality. Microcrystals for SFX data collection were prepared in gas-tight syringes (Hamilton) as previously described 23 . After optimization, diffraction-quality crystals were obtained from 100 mM ADA pH 5.8-6.5, 24-28% (vol/vol) PEG 400, 10-200 mM NH 4 CH 3 CO 2 , 50 μM 2-PMT or ramelteon, by injecting 5 μl of proteinladen LCP into 50 μl precipitant in syringes. Before loading the microcrystals into the LCP injector, excess precipitant was removed and 7.9 monoacylglycerol (MAG) lipid was added to the LCP to absorb any residual precipitant solution and to prevent crystalline phase formation upon rapid cooling when injecting LCP into vacuum 24 . Crystallographic data collection. Data collection was performed at the Coherent X-ray Imaging (CXI) 25 end station of the Linac Coherent Light Source (LCLS), which operated at a wavelength of 1.3 Å (9.83 keV) delivering individual X-ray pulses of 30 and 43 fs pulse duration and approximately 10 11 photons per pulse focused into a spot size of approximately 1.5 μm in diameter using a pair of Kirkpatrick-Baez mirrors. Microcrystals (Extended Data Fig. 1c ) of MT 2 (approximately 5 × 5 × 5 μm 3 ) were delivered in the LCP medium using an LCP microextrusion injector 24 with 50-μm nozzle running at a flow rate of approximately 300 nl min −1 . Diffraction images were recorded at a rate of 7,200 patterns per minute (120 Hz) with the 2.3 Megapixel Cornell-SLAC Pixel Array Detector (CSPAD) 26 . Initial diffraction frames were corrected and filtered using the software package Cheetah 27 . A crystal 'hit' was defined as an image containing a minimum of 20 diffraction peaks with a signal-to-noise ratio above 4 and a number of pixels above 3. After further refinement of parameters (peak detection, prediction and integration), images were indexed using MOSFLM 28 , DirAx 29 , and XDS 30 and integrated and merged into a final dataset using CrystFEL v.0.6.2 software suite 31 . Integration radii of 3, 5, and 6 pixels with per pattern resolution cut-offs 1.0 nm -1 above the conservative resolution estimates for each crystal were applied (push-res option), otherwise default values were used. The total numbers of collected images/hits/indexed images are as follows: 2,154,963/84,928/31,677 (MT 2 -CC-2-PMT), 476,863/59,071/28,130 (MT 2 -CC(H208A)-2-PMT), 293,060/22,267/20,704 (MT 2 -CC(N86D)-2-PMT), 727,004/60,005/28,834 (MT 2 -CC-ramelteon). As a resolution cutoff, the criterion 32 of CC * >0.5 was used for all datasets (see Extended Data Table 2 for data statistics). The space group was determined to be P2 1 , with two molecules per asymmetric unit. Structure determination. To solve the 2.8 Å resolution MT 2 -CC-2-PMT structure, a search model was generated as follows: the MT 2 receptor sequence was sent to the HHpred server 33 , and the output models were reduced by removing all low-resolution (<3.0 Å) and NMR structures. The RCSB Protein Data Bank (PDB) files of the top ten hits were downloaded and prepared with Sculptor 34 . The models were structurally superimposed, and the side chains were pruned, yielding the conserved receptor core model. The model that produced a successful molecular replacement solution with Phaser 35 (TFZ score of 14.9 and LLG of 320) was based on the C-C chemokine receptor 2 structure (PDB ID: 5T1A) 36 . This solution containing two receptor molecules was fixed as a partial solution, and the search continued with rubredoxin (PDB ID: 1IRO), in which one molecule was placed in the asymmetric unit. The resulting three-component solution was subjected to several rounds of refining with phenix.refine 37 and model building with phenix.autobuild 38 followed by manual refinement in Coot 39 . BRIL (PDB ID: 1M6T) was then used independently as a search model for remaining fusion partners in the asymmetric unit. The second BRIL was manually modelled into the electron density; however, no density could be found for the second rubredoxin molecule, which, therefore, was not modelled in the final structure. This rubredoxin fusion partner is likely to be disordered and does not participate in crystal contacts, however, there is space for it in the crystal lattice (Extended Data Fig. 1d) . A zinc ion was modelled in rubredoxin as previously described 40 . Ligand restraints for refinement of 2-PMT and ramelteon coordinates were generated by Prodrg 43 . For the other three datasets, the MT 2 -CC-2-PMT structure was used as a search model for molecular replacement, and the refinement procedure was repeated as described above. The Ramachandran plot obtained by MolProbity 44 shows that, with the exception of Y92 from the YPYP motif, all residues are in the favoured/allowed regions: 95.4/4.4% of residues (MT 2 -CC-2-PMT), 93/6.8% of residues (MT 2 -CC(H208A)-2-PMT), 94.8/5.0% of residues (MT 2 -CC(N86D)-2-PMT), 95.3/4.5% of residues (MT 2 -CC-ramelteon).
Data collection and refinement statistics are summarized for each structure in
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Extended Data were docked into the 2-PMT-bound crystal structures using an energy based docking in ICM-Pro v3.8-6 47 as described in the accompanying paper 8 . Molecular dynamics simulations. The experimental structure of MT 2 was prepared and subjected to molecular dynamics simulations as described in the accompanying paper 8 . The simulation periodic box had dimensions (x, y, z) of 75.5 Å, 75.5 Å, 105.4 Å, and contained lipids (129 POPC molecules), 10,281 water molecules, 26 sodium ions, and 36 chloride ions. Radioligand binding assays. Equilibrium binding assays were performed and analysed as described in the accompanying paper 8 . HEK293T cells were obtained from ATCC (CRL-11268, authenticated by supplier using morphology, growth characteristics and short tandem repeat profiling, certified mycoplasma-free). For kinetic studies, to initiate dissociation of [ 3 H]melatonin, 10 μl of cold excess melatonin (10 μM) was added per well at specific time points ranging from 2 min to 10 h, and immediately at time = 0 min plates were collected. Dissociation experiments were performed at 25 °C for MT 1 and 37 °C for MT 2 because of the slow kinetics in MT 2 . For all assays, non-specific activity was defined by the addition of 5 μM 2-PMT. Ligand dissociation data were analysed using 'Dissociation-One phase exponential decay' to yield estimates of k off using GraphPad Prism 7.0. MT 2 G i/o -mediated cAMP inhibition assay. MT 2 G i/o -mediated cAMP inhibition assays were performed in HEK293T cells as described in the accompanying paper 8 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Data availability
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample size. Thermostability and pharmacological characterization were conducted at least in n=3 independent experiments and are comparable to other published studies. Wild-type constructs were used as internal controls, resulting in larger number of independent repeats. Diffraction data from thousands of protein crystals were integrated and scaled to ensure 100% completeness of the dataset.
Data exclusions No data were excluded.
Replication
All measurements were done in triplicate and all attempts at replication were successful and presented.
Randomization This study did not allocate experimental groups thus no randomization was required for the reported experiments.
Blinding
The researchers were not blinded to allocation during experiments and outcome assessment. Blinding was not required for the reported experiments because all functional and structural data were analyzed using the same methods, and results are not subjective.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Authentication
The cell lines were authenticated by the supplier (ATCC) using morphology and growth characteristics (for Sf9 and HEK293T), and STR profiling (for HEK293T).
Mycoplasma contamination
Both Sf9 and HEK293T cells have been tested and shown to be free from mycoplasma (Hoechst DNA strain and Direct Culture methods employed).
